Arno Therapeutics to Present at Upcoming Investor Conferences
September 08, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update
August 14, 2014 16:49 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer
July 18, 2014 16:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
May 29, 2014 16:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
Arno Therapeutics Reports First Quarter 2014 Financial and Business Update
May 15, 2014 16:40 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men's and Women's Cancers at 2014 ASCO Annual Meeting
May 14, 2014 17:00 ET
|
Arno Therapeutics Inc.
Studies to determine recommended Phase II dose and safety profile of lead compound
Will analyze relationship of biomarker to any anti-tumor activity observed
FLEMINGTON, N.J., May 14, 2014...
Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting
May 05, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer
April 07, 2014 10:42 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 7, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones
April 01, 2014 09:10 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 1, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014
March 26, 2014 08:45 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...